iShares Genomics Immunology and Healthcare ETF (IDNA)

Key Metrics

TER 0.47% per year

Distribution policy Distributing

Fund size USD 191 M

Inception date June 10, 2019

Holdings 61

Fund currency USD

Fund domicile US

Provider iShares

For full official fund details, factsheets, and holdings, visit ishares.com (opens in new tab).

Historical Return

Last updated: Oct 01, 2026

1 Year +73.9% +0.7% Div

3 Years (avg.) +28.8% +0.7% Div

5 Years (avg.) -3.2% +0.7% Div

Risk & Analysis Metrics

Last updated: Oct 01, 2026

Volatility

25.28% 1 Year

25.11% 3 Years

28.26% 5 Years

29.23% 10 Years

Max Drawdown

-10.55% 1 Year

-29.75% 3 Years

-66.17% 5 Years

-68.69% 10 Years

Sharpe Ratio

1.92 1 Year

0.91 3 Years

-0.12 5 Years

0.24 10 Years

Return Triangle (Heatmap)

Last updated: Oct 01, 2026

	2019	2020	2021	2022	2023	2024	2025
2019	19.9%	36.4%	20.8%	0.3%	-1.5%	-1.8%	0.5%
2020		55.1%	21.3%	-5.5%	-6.2%	-5.6%	-2.4%
2021			-5.2%	-26.3%	-20.7%	-16.6%	-11.1%
2022				-42.6%	-27.4%	-20.1%	-12.5%
2023					-8.2%	-5.8%	0.7%
2024						-3.2%	5.5%
2025							15.1%

Distributions

*by ETF Portfolio Weight Last updated: Oct 01, 2026

Profit Margin Distribution

< 0%

46%

1y 3y N/A N/A

0 - 5%

1y 3y N/A N/A

5 - 10%

16%

1y 3y N/A N/A

10 - 15%

1y 3y N/A N/A

15 - 20%

1y 3y N/A N/A

20 - 30%

1y 3y N/A N/A

30 - 40%

1y 3y N/A N/A

> 40%

1y 3y N/A N/A

P/E Ratio Distribution

< 0

48%

1y 3y N/A N/A

0 - 10

1y 3y N/A N/A

10 - 15

1y 3y N/A N/A

15 - 20

15%

1y 3y N/A N/A

20 - 25

14%

1y 3y N/A N/A

25 - 35

16%

1y 3y N/A N/A

35 - 50

1y 3y N/A N/A

> 50

1y 3y N/A N/A

Discounted Cash Flow

Weighted Average Undervaluation

N/A

Undervalued

> 60%

1y 3y N/A N/A

45 - 60%

1y 3y N/A N/A

30 - 45%

1y 3y N/A N/A

15 - 30%

1y 3y N/A N/A

Fair (±15%)

1y 3y N/A N/A

Overvalued

15 - 30%

1y 3y N/A N/A

30 - 45%

1y 3y N/A N/A

45 - 60%

1y 3y N/A N/A

> 60%

1y 3y N/A N/A

Market Cap Size Distribution

Micro Cap

0.0%

1y 3y N/A N/A

Small Cap

15.2%

1y 3y N/A N/A

Mid Cap

10.1%

1y 3y N/A N/A

Large Cap

67.6%

1y 3y N/A N/A

Mega Cap

7.2%

1y 3y N/A N/A

Micro: < $300M Small: $300M–$2B Mid: $2B–$10B Large: $10B–$200B Mega: > $200B

Average metrics of all companies in portfolio

Last updated: Oct 04, 2026

Market
Average

Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares.	$74.4B	-
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price.	0.86%	2.02%
Beta Indicates the relationship between the price performance of a share and the market.	0.85	-
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth.	27.32	23.08
Negative P/E Ratio a negative P/E ratio shows that the company is not profitable, and it shows how many years it would take the company to lose its entire market capitalisation if it did not change anything	-24.84	-
Profitable Companies	50%	-
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued.	23.7	19.24
Price to Sales Ratio Market cap divided by the revenue in the most recent year.	11.93	9.85
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company	7.11	12.6

Market
Average

Enterprise Value to EBIT Enterprise Value divided by EBIT	-5.37	11.97
Enterprise Value to Revenue Enterprise value divided by revenue	13.18	13.3
Total Debt to Enterprise Value Total debt divided by enterprise value	0.16	0.04
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary.	0.38	0.32
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability.	-27.36%	21.62%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago.	-26.7%	+55.1%
Return on Equity Equity divided by market cap.	-1.59%	1.73%
Return on Assets Indicates a company's profitability in relation to its total assets.	-6.63%	3.97%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits.	-2.78%	3.60%

Sectors

Manufacturing	31.5%
Professional, Scientific, and Technical Services	11.8%
Health Technology	7.3%
Health Care and Social Assistance	0.9%
Other	48.4%

Countries

United States	66.0%
Germany	7.0%
France	5.6%
Japan	4.9%
Switzerland	4.4%
Denmark	4.0%
United Kingdom	2.7%
Canada	2.6%
China	1.8%
Luxembourg	0.6%
South Korea	0.2%
Other	0.2%

Limit holdings to companies in a single sector.

$0B >$1T

Ratio between share price and earnings per share. A low ratio could indicate undervaluation.

<0 >50

Ratio of dividends in the last 12 months to current share price.

0% 3%

Revenue increase compared to the same quarter one year ago.

0% 30%

Net income increase compared to the same quarter one year ago.

0% 30%

Profitability of the last quarter.

<-30% >30%

A higher ratio indicates a higher risk. The ratio is difficult to compare between industries.

<0 >3

Discounted cash flow valuation vs. current price. Positive = undervalued, negative = overvalued.

<-50% >+100%

Market Cap

P/E Ratio

Total Investment

Weight

Twist Bioscience Corp

TWST - Professional, Scientific, and Technical Services

Market Cap $11.75B

P/E Ratio -85.0

Dividends 0.0%

Total Investment $9.15M

Weight 4.79%

Loading details…

Regeneron Pharmaceuticals, Inc.

REGN - Manufacturing

Market Cap $75.74B

P/E Ratio 17.6

Dividends 0.5%

Total Investment $8.3M

Weight 4.35%

Loading details…

Genmab - ADR

GMAB - Professional, Scientific, and Technical Services

Market Cap $21.33B

P/E Ratio 26.5

Dividends 0.0%

Total Investment $8.08M

Weight 4.23%

Loading details…

Moderna Inc

MRNA - Manufacturing

Market Cap $75.39B

P/E Ratio -23.8

Dividends 0.0%

Total Investment $7.99M

Weight 4.19%

Loading details…

Takeda Pharmaceutical Co - ADR

TAK - Manufacturing

Market Cap $56.83B

P/E Ratio 49.4

Dividends 3.6%

Total Investment $7.73M

Weight 4.05%

Loading details…

Vertex Pharmaceuticals, Inc.

VRTX - Manufacturing

Market Cap $128.1B

P/E Ratio 29.1

Dividends 0.0%

Total Investment $7.39M

Weight 3.87%

Loading details…

Roche Holding AG

RHHVF - Health Technology

Market Cap $334.58B

P/E Ratio 22.5

Dividends 2.8%

Total Investment $7.34M

Weight 3.85%

Loading details…

BioNTech SE - ADR

BNTX - Manufacturing

Market Cap $24.34B

P/E Ratio -12.7

Dividends 0.0%

Total Investment $7.11M

Weight 3.73%

Loading details…

GSK Plc - ADR

GSK - Manufacturing

Market Cap $94.22B

P/E Ratio 14.8

Dividends 3.8%

Total Investment $6.93M

Weight 3.63%

Loading details…

Sanofi - ADR

SNY - Health Technology

Market Cap $95.86B

P/E Ratio 21.7

Dividends 11.8%

Total Investment $6.61M

Weight 3.46%

Loading details…

Iovance Biotherapeutics Inc

IOVA - Manufacturing

Market Cap $6.35B

P/E Ratio -20.3

Dividends 0.0%

Total Investment $3.43M

Weight 1.80%

Loading details…

CRISPR Therapeutics AG

CRSP - Manufacturing

Market Cap $5.35B

P/E Ratio -11.6

Dividends 0.0%

Total Investment $2.99M

Weight 1.57%

Loading details…

AbCellera Biologics Inc

ABCL

Market Cap $4.2B

P/E Ratio -25.4

Dividends 0.0%

Total Investment $2.91M

Weight 1.52%

Loading details…

Vir Biotechnology Inc

VIR - Professional, Scientific, and Technical Services

Market Cap $1.88B

P/E Ratio -6.0

Dividends 0.0%

Total Investment $2.51M

Weight 1.31%

Loading details…

Janux Therapeutics Inc

JANX - Professional, Scientific, and Technical Services

Market Cap $1.03B

P/E Ratio -10.3

Dividends 0.0%

Total Investment $1.88M

Weight 0.99%

Loading details…

Corvus Pharmaceuticals Inc

CRVS - Manufacturing

Market Cap $916.59M

P/E Ratio -17.0

Dividends 0.0%

Total Investment $1.82M

Weight 0.95%

Loading details…

Personalis Inc

PSNL - Health Care and Social Assistance

Market Cap $1.74B

P/E Ratio -14.9

Dividends 0.0%

Total Investment $1.7M

Weight 0.89%

Loading details…

Kura Oncology Inc

KURA - Manufacturing

Market Cap $945.45M

P/E Ratio -3.2

Dividends 0.0%

Total Investment $1.68M

Weight 0.88%

Loading details…

CytomX Therapeutics Inc

CTMX - Manufacturing

Market Cap $557.32M

P/E Ratio -5.7

Dividends 0.0%

Total Investment $1.17M

Weight 0.61%

Loading details…

Alvotech

ALVO

Market Cap $2.41B

P/E Ratio -9.3

Dividends 0.0%

Total Investment $1.01M

Weight 0.53%

Loading details…

Key Metrics

Compare similar ETFs

Historical Return

Risk & Analysis Metrics

Volatility

Max Drawdown

Sharpe Ratio

Return Triangle (Heatmap)

Distributions

Profit Margin Distribution

P/E Ratio Distribution

Discounted Cash Flow

Market Cap Size Distribution

Portfolio Concentration

Latest News

Moderna stock rises 2% on Nasdaq 100 entry but this analyst says sell

Moderna to replace Warner Bros Discovery on Nasdaq 100

Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026

Average metrics of all companies in portfolio

Sectors

Countries

Stock Screener

Twist Bioscience Corp

Twist Bioscience Corp

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

Genmab - ADR

Genmab - ADR

Moderna Inc

Moderna Inc

Takeda Pharmaceutical Co - ADR

Takeda Pharmaceutical Co - ADR

Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals, Inc.

Roche Holding AG

Roche Holding AG

BioNTech SE - ADR

BioNTech SE - ADR

GSK Plc - ADR

GSK Plc - ADR

Sanofi - ADR

Sanofi - ADR

Iovance Biotherapeutics Inc

Iovance Biotherapeutics Inc

CRISPR Therapeutics AG

CRISPR Therapeutics AG

AbCellera Biologics Inc

AbCellera Biologics Inc

Vir Biotechnology Inc

Vir Biotechnology Inc

Janux Therapeutics Inc

Janux Therapeutics Inc

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Personalis Inc

Personalis Inc

Kura Oncology Inc

Kura Oncology Inc

CytomX Therapeutics Inc

CytomX Therapeutics Inc

Alvotech

Alvotech

Cookie Settings